019/2018

Question Booklet Alpha Code



Question Booklet Serial Number

| Total Number of Questions : 100 | Time: 75 Minutes |
|---------------------------------|------------------|
| Maximum Marks: 100 | |

INSTRUCTIONS TO CANDIDATES

- 1. The question paper will be given in the form of a Question Booklet. There will be four versions of question booklets with question booklet alpha code viz. **A**, **B**, **C** & **D**.
- 2. The Question Booklet Alpha Code will be printed on the top left margin of the facing sheet of the question booklet.
- 3. The Question Booklet Alpha Code allotted to you will be noted in your seating position in the Examination Hall.
- 4. If you get a question booklet where the alpha code does not match to the allotted alpha code in the seating position, please draw the attention of the Invigilator IMMEDIATELY.
- 5. The Question Booklet Serial Number is printed on the top right margin of the facing sheet. If your question booklet is un-numbered, please get it replaced by new question booklet with same alpha code.
- 6. The question booklet will be sealed at the middle of the right margin. Candidate should not open the question booklet, until the indication is given to start answering.
- 7. Immediately after the commencement of the examination, the candidate should check that the question booklet supplied to him contains all the 100 questions in serial order. The question booklet does not have unprinted or torn or missing pages and if so he/she should bring it to the notice of the Invigilator and get it replaced by a complete booklet with same alpha code. This is most important.
- 8. A blank sheet of paper is attached to the question booklet. This may be used for rough work.
- 9. Please read carefully all the instructions on the reverse of the Answer Sheet before marking your answers.
- 10. Each question is provided with four choices (A), (B), (C) and (D) having one correct answer. Choose the correct answer and darken the bubble corresponding to the question number using Blue or Black Ball Point Pen in the OMR Answer Sheet.
- 11. Each correct answer carries 1 mark and for each wrong answer 1/3 mark will be deducted. No negative mark for unattended questions.
- 12. No candidate will be allowed to leave the examination hall till the end of the session and without handing over his/her Answer Sheet to the Invigilator. Candidates should ensure that the Invigilator has verified all the entries in the Register Number Coding Sheet and that the Invigilator has affixed his/her signature in the space provided.
- 13. Strict compliance of instructions is essential. Any malpractice or attempt to commit any kind of malpractice in the Examination will result in the disqualification of the candidate.



019/2018

| 1. | The | largest inland sal | lt wat | er lake in Iı | ndia, 1 | namely | y Sambhar Lake | is loca | nted in |
|----|-------------|--|---------|----------------|---------|-------------------|------------------|---------|-----------------------------------|
| | (A) | Orissa | (B) | Bihar | | (C) | West Bengal | (D) | Rajasthan |
| 2. | Of t | he following rive | rs whi | ich is the tri | ibutar | y of N | armada ? | | |
| | (A) | Musi | (B) | Indravati | • | (C) | Hiran | (D) | Kapila |
| 3. | Gon | nal and Bolan Pas | sses r | un through | the _ | | | | |
| | (A) | Himalayas | | | (B) | Wes | tern Ghats | | |
| | (C) | Aravalli Hills | | | (D) | Vinc | lhya-Satpura ra | nges | |
| 4. | Whi 1857 | | e the f | ollowing ar | gumei | nt whi | le analyzing the | charac | eter of the Revolt of |
| | | e revolt of 1857 c ugh the sentimen | | U | | | | | sense of the word. ontent in it." |
| | (A) | Susobhan Sarka | ar | | (B) | A.R. | Desai | | |
| | (C) | S.B. Chaudhuri | | | (D) | P.C. | Joshi | | |
| 5. | The | 'Quit India' resol | lution | was passed | l by th | ne Bor | nbay session of | the AI | CC on |
| | (A) | 9 th August 1942 | 2 | | (B) | 8 th A | August 1942 | | |
| | (C) | 6 th August 1942 | 2 | | (D) | 7 th A | August 1942 | | |
| 6. | | o formed a <i>Samiti</i> r | | • | | | | spread | swadeshi messages |
| | (A) | Bipin Chandra | Pal | | (B) | Muk | tunda Das | | |
| | (C) | Ashwin Kumar | Dutt | | (D) | Lala | Lajpat Rai | | |
| 7. | | o among the followement? | llowi | ng freedor | n figl | nter w | vas NOT assoc | ciated | with the Ghadar |
| | (A) | Lala Hardayal | (B) | Ram Cha | ndra | (C) | Barkathullah | (D) | B.K. Dutt |
| 8. | Who | played a leading | g role | in drafting | the Fi | ve Ye | ar Plan of 1956- | 61 ? | |
| | (A) | Prof. P.C. Maha | alanob | ois | (B) | Prof. | . K.N. Raj | | |
| | (C) | V.K.R.V. Rao | | | (D) | | Chandra Bose | | |
| | | | | | | | | | |

| 9. | Porkalam, Cheramangad and Pazha Kerala. | | | | | | | • | | | | | sites excavated in |
|------------|--|---|----------------|------------------|-------------|-------------------|---------|--------|------------|------------------------------|---------------------------------|---------|----------------------------|
| | (A) | Meg | aliths | | (B) | Meso | olithic | | (C) | Neolitl | nic | (D) | Palaeolithic |
| 10. | | | ss in Idukl | | | n Gha | t coni | nects | Madı | ırai dist | rict in T | amilna | du with the High |
| | (A) | Aru | vaimo | zhi Pa | ass | | | (B) | Pera | ımbadi I | Pass | | |
| | (C) | Bod | inayal | kannu | r Pass | 5 | | (D) | Peri | ya Pass | | | |
| 11. | Amo | ong th | e follo | owing | work | s whic | ch one | e is w | ritten | by Brah | manand | a Sivay | yogi ? |
| | (A) | Prac | heena | a Mala | ayalar | n | | (B) | Mol | kshaprac | leepam | | |
| | (C) | Jath | ikkum | ımy | | | | (D) | Ved | adhikara | a Niroop | anam | |
| 12. | | Name the social reformer and poet of and <i>Kavitilakan</i> from Valiya Tampura | | | | | | | | | d the titl | es nam | nely <i>Sahityanipunan</i> |
| | (A) | Kun | naran | asan | | | | (B) | Ven | gayil Ku | ınhirama | an Nai | • |
| | (C) | Thy | caud . | Ayya | | | | (D) | Pan | dit Karu | ppan | | |
| 13. | lead (A) | er shi Kun | | vhich Guru | social | 31 froi reforn | | | la. Ayy | sargod o rankali Palpu | on foot, v | was co | nducted under the |
| 14. | the ' | wome Atm | n div a Vid | ision (ya Sa | of nghar | | · | | (B) (D) | Yogak | vani wero shema S aha Sab | abha | nportant leaders of |
| 15. | Mate | ch the | follo | wing v | with t | he helj | p of tl | ne CC | DDES | given be | low: | | |
| | (a) | Poik | ayil Y | ohan: | nan | | (i) | Sam | atwa | Samajaı | m | | |
| | (b) | Pan | dit Ka | ruppa | an | | (ii) | Ural | lunka | l AikyaN | Janaya S | Sangha | m |
| | (c) | Vag | bhata | nanda | a | | (iii) | Prat | hyksh | na Raksh | a Daiva | Sabha | |
| | (d) | Ayy | a Vai | kunda | ır | | (iv) | Cocl | hin Pı | ulaya Ma | aha Sabl | na | |
| | Cod | es: | | | | | | | | | | | |
| | | (a) | (b) | (c) | (d) | | | | | | | | |
| | (A) | (i) | (ii) | (iv) | (iii) | | | | | | | | |
| | (B) | (iii) | (iv) | (ii) | (i) | | | | | | | | |
| | (C) | (ii) | (i) | (iii) | (iv) | | | | | | | | |
| | (D) | (iv) | (iii) | (i) | (ii) | | | | | | | | |

| 16. Name Japan's men-only island recommended by UNESCO to its World Heritage list in 2017. | | | | | | | Heritage list in May | | |
|---|--------|-------------------------------------|--------------------|-------------------------|--------------------|--------|----------------------|-----------|------------------------------|
| | (A) | Okinawa | (B) | Honshu | | (C) | Amami Oshi | ma (D) | Okinoshima |
| 17. | | o has been appoi he Central Gove | | .* | | | | | Certification (CBFC) years ? |
| | (A) | Pahlaj Nihala | ni | | (B) | Pras | soon Joshi | | |
| | (C) | Anurag Srivas | stava | | (D) | Mul | kesh Bhatt | | |
| 18. | Nan | ne the snake bo | at whic | h won the 6 | 65 th N | ehru | Trophy Boat R | ace on F | Punnamada Lake. |
| | (A) | Mahadevikad | Chund | lan | (B) | Pay | ippadan Chun | dan | |
| | (C) | Karichal Chu | ndan | | (D) | Gab | riel Chundan | | |
| 19. | | among the foll Stephen Hawki | | | | | | | nan Albert Einstein |
| | (A) | Rajgauri Paw | ar | | (B) | Rajr | nukhi Pawar | | |
| | (C) | Mukta Pawar | | | (D) | Nee | lam Pawar | | |
| 20. | Whi | ch is the curren | cy of Re | epublic of K | Ciribat | i ? | | | |
| | (A) | U.S. Dollar | | | (B) | New | v Zealand Doll | ar | |
| | (C) | Australian Do | llar | | (D) | Kina | a | | |
| 21. | Reg | ulatory authorit | y for th | e use of rac | liopha | armac | euticals in Indi | a : | |
| | (A) | FDA | (B) | AERB | | (C) | RPC | (D) | All the above |
| 22. | If 99: | ^m Tc-MDP conta | ins ^{99m} | Tc-pertechn | etate | as an | impurity it wi | ll be acc | umulated in : |
| | (A) | Bone | (B) | Liver | | (C) | Thyroid | (D) | All of the above |
| 23. | Radi | iochemical impu | ırity ex | pected in ⁹⁹ | ^{om} Tc e | luates | s is : | | |
| | (A) | Reduced hydr | olysed | technetium | (B) | Mol | ybdenum - 98 s | species | |
| | (C) | Molybdenum | - 99 spe | ecies | (D) | Sodi | ium Pertechne | tate | |
| 24. | B.E. | Γ Stands for : | | | | | | | |
| | (A) | Bacterial Endo | otoxin T | est | (B) | Bact | erial Environm | nent Test | t |
| | (C) | Biosafety Exha | aust Tes | st | (D) | Bact | erial Exotoxin | Test | |
| A | | | | | 5 | | | | 019/2018 |

| 25. | In a | Symbol ¹³¹ I, the number 131 stand | ls for | : |
|------------|------------------|--|---------|--|
| | (A) | number of neutrons | (B) | number of protons |
| | (C) | number of electrons | (D) | number of nucleons |
| 26. | The | presence of chemical impurities in | 99mTc | c-compounds will lead to : |
| | (A) | undue toxicity | (B) | Poor labelling |
| | (C) | both (A) and (B) | (D) | None of the above |
| 27. | 99m' | Tc-MIBI accumulates in myocardio | ım by | ·: |
| | (A) | Active transport | (B) | Passive diffusion |
| | (C) | Chemisorption | (D) | Compartment localisation |
| 28. | Cadı | mium rod is used in Nuclear React | tor as | : |
| | (A) | Moderator | (B) | Cladding material |
| | (C) | Fuel | (D) | Control rod |
| 29. | In a | period of six half lives, the activity | of a 1 | material reduces to : |
| | (A) | 1/16 of its initial activity | (B) | 1/8 of its initial activity |
| | (C) | 1/32 of its initial activity | (D) | 1/64 of its initial activity |
| 30. | Enu | meration of microbial contamination | on in e | environment is indicated by: |
| | (A) | Colour development | (B) | Spore development |
| | (C) | Colony development | (D) | None of the above |
| 31. | ⁹⁹ Mo | o- ⁹⁹ Tc generator system belongs to | : | |
| | (A) | transient equilibrium | (B) | no equilibrium |
| | (C) | secular equilibrium | (D) | None of the above |
| 32. | The | most popular Bone imaging agent | is: | |
| | (A) | 99mTc-MDP (B) 18F-NaF | | (C) Tc-99m HEDP (D) F-18 FDG |
| 33. | | inct property of ²⁰¹ Thallium Chlo nnetium-99m agents. | ride i | n Myocardial perfusion imaging compared to |
| | (A) | infarct uptake | (B) | myocardial uptake |
| | (C) | redistribution | (D) | tumour uptake |
| | | | | |

| 34. | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | c(v)-DNISA is useful for imaging | : | | | | | | | | |
|------------|---|--|--------------|---|--|--|--|--|--|--|--|
| | (A) | Colorectal cancer | (B) | Medullary thyroid cancer | | | | | | | |
| | (C) | Differentiated thyroid cancer | (D) | Ovarian cancer | | | | | | | |
| 35. | 99m' | Tc-ECD is preferable to 99mTc-HN | л Р АО | because of : | | | | | | | |
| | (A) | ease of preparation | (B) | higher brain uptake | | | | | | | |
| | (C) | stereo specificity | (D) | in vitro stability | | | | | | | |
| | (0) | stereo specificity | (D) | III vitto stability | | | | | | | |
| 36. | Radi | ioimmunoscintigraphy is based on | : | | | | | | | | |
| | (A) | Immunotargetting | (B) | Receptor binding | | | | | | | |
| | (C) | Avidin-biotin system | (D) | None of the above | | | | | | | |
| 37. | Iodii | ne-123 is commercially obtained fr | om: | | | | | | | | |
| | (A) | Cyclotron (B) Generator | | (C) Reactor (D) All of the above | | | | | | | |
| | | | | | | | | | | | |
| 38. | | best radiographic technique for ea | • | | | | | | | | |
| | (A) | Computed tomography | (B) | Endoscopic ultrasound | | | | | | | |
| | (C) | Positron Emission Tomography | (D) | Double contrast barium study | | | | | | | |
| 39. | ²⁰¹ Thallous Chloride enters the myocardium by : | | | | | | | | | | |
| | (A) | Reverse Osmosis | (B) | Na ⁺ - K ⁺ ATPase pump | | | | | | | |
| | (C) | Passive Diffusion | (D) | None of the above | | | | | | | |
| 40. | Biolo | ogical Quality control testing inclu | des : | | | | | | | | |
| | | Pyrogen test | | Sterility test | | | | | | | |
| | (C) | Biodistribution studies | (D) | All of the above | | | | | | | |
| | | | | | | | | | | | |
| 41. | | adioimmunoassay, the relation begen in the test sample is: | tween | intensity of radioactivity and concentration of | | | | | | | |
| | (A) | Inverse (B) Direct | | (C) Exponential (D) No relation | | | | | | | |
| 42. | Gene | erator produced PET Tracer : | | | | | | | | | |
| | (A) | Rubidium - 81 | (B) | Technetium - 99m | | | | | | | |
| | (C) | Gallium - 68 | (D) | Indium - 113m | | | | | | | |
| | | | | | | | | | | | |

| Dose | limiting organ | in mos | st radionucli | de the | erapie | s. | | | |
|-------|---|---|--|--|--|--|--|--|--|
| (A) | Kidney | (B) | Bone mar | row | (C) | Colon | (D) | Liver | |
| | | | | | | | | | |
| | O | • | rdial perfus | | 0 0 | | | | |
| ` ′ | | | | ` ' | | | | | |
| (C) | ^{99m} Tc-MIBI | | | (D) | ²⁰¹ T] | nallium Chloi | ride | | |
| Criti | cal Organ in 991 | mTc-M | IBI myocard | dial pe | erfusio | on imaging : | | | |
| (A) | Heart | (B) | Proximal | colon | (C) | Liver | (D) | Stomach | |
| Half | life of Iodine-13 | 31: | | | | | | | |
| (A) | 3 days | (B) | 13.6 hours | 5 | (C) | 8 days | (D) | 60 days | |
| Radi | oisotope used fo | or pain | ful bone me | tastas | is : | | | | |
| (A) | Samarium 153 | | | (B) | Iodiı | ne 131 | | | |
| (C) | Technetium 99 | m | | (D) | Galli | ium 67 | | | |
| 99mT | c-sodium pertec | hnetat | e can be use | ed for | all the | e following e | xcept : | | |
| (A) | | | | (B) | | | | | |
| (C) | Infection imag | ing | | (D) | Mec | kels diverticu | lum detec | tion | |
| Whe | n performing Io | dine-12 | 23 imaging, | breas | t feed | ing can be sat | fely resun | ned after ? | |
| (A) | 2 - 3 days | | 0 0 | (B) | 12 to | 24 hours | J | | |
| (C) | 4 hours | | | (D) | cann | ot be resume | ed | | |
| Ener | gy of Gamma ra | nys emi | itted in Posi | tron E | missi | on Tomograp | hy: | | |
| | . | • | | | | 0 1 | (D) | 185 keV | |
| Incid | lence of thyroid | cancer | is higher i | n whic | ch thy | roid scintigra | iphy patte | ern ? | |
| | • | | O | | - | _ | | | |
| (C) | | ncreas | ed uptake | (D) | | 2 | 1 | | |
| Most | t common false | positiv | e finding in | parat | hvroid | d scanning : | | | |
| | • | _ | | • | • | 0 | ioma | | |
| (C) | • | | nsia | ` / | | 2 | | | |
| ` / | , , | Perpre | ioiu | (D) | 11001 | vity in oropin | arynx | | |
| | (A) PET (A) (C) Critic (A) Half (A) (C) 99mT (A) (C) Whe (A) (C) Ener (A) Incid (A) (C) Most (A) | (A) Kidney PET Agent used for (A) 13N-Ammonia (C) 99mTc-MIBI Critical Organ in 99m (A) Heart Half life of Iodine-13m (A) 3 days Radioisotope used for (A) Samarium 153m (C) Technetium 99m (C) Infection imaging (C) Infection imaging (C) Infection imaging (C) 4 hours Energy of Gamma radio (A) 2 - 3 days (C) 4 hours Energy of Gamma radio (A) 140 keV Incidence of thyroid (A) Hot nodule (C) Homogenous in Most common false (A) Thyroid adence (C) | (A) Kidney (B) PET Agent used for myoca (A) ¹³ N-Ammonia (C) ^{99m} Tc-MIBI Critical Organ in 99mTc-M (A) Heart (B) Half life of Iodine-131: (A) 3 days (B) Radioisotope used for pain (A) Samarium 153 (C) Technetium 99m 99mTc-sodium pertechnetat (A) Thyroid imaging (C) Infection imaging (C) Infection imaging When performing Iodine-12 (A) 2 - 3 days (C) 4 hours Energy of Gamma rays emit (A) 140 keV (B) Incidence of thyroid cancer (A) Hot nodule (C) Homogenous increase Most common false positiv (A) Thyroid adenoma | (A) Kidney (B) Bone mark PET Agent used for myocardial perfuse (A) 13N-Ammonia (C) 99mTc-MIBI Critical Organ in 99mTc-MIBI myocard (A) Heart (B) Proximal of Half life of Iodine-131: (A) 3 days (B) 13.6 hours Radioisotope used for painful bone met (A) Samarium 153 (C) Technetium 99m 99mTc-sodium pertechnetate can be used (A) Thyroid imaging (C) Infection imaging When performing Iodine-123 imaging, (A) 2 - 3 days (C) 4 hours Energy of Gamma rays emitted in Position (A) 140 keV (B) 511 keV Incidence of thyroid cancer is higher in (A) Hot nodule (C) Homogenous increased uptake Most common false positive finding in (A) Thyroid adenoma | (A) Kidney (B) Bone marrow PET Agent used for myocardial perfusion in (A) ¹³ N-Ammonia (B) (C) ^{99m} Tc-MIBI (D) Critical Organ in 99mTc-MIBI myocardial perfusion in (A) Heart (B) Proximal colon (A) Heart (B) Proximal colon (B) (B) (C) Technetium (B) (C) Technetium (C) (D) (D) (D) (D) (D) (D) (D) (D) (D) (D | (A) Kidney (B) Bone marrow (C) PET Agent used for myocardial perfusion imaging (A) 13N-Ammonia (B) 18F-I (C) 99mTc-MIBI (D) 201TI Critical Organ in 99mTc-MIBI myocardial perfusion (A) Heart (B) Proximal colon (C) Half life of Iodine-131: (A) 3 days (B) 13.6 hours (C) Radioisotope used for painful bone metastasis: (A) Samarium 153 (B) Iodin (C) Technetium 99m (D) Gallin (C) Technetium 99m (D) Gallin (C) Infection imaging (B) Saliv (C) Infection imaging (D) Mecial (C) Infection imaging (D) Mecial (C) 4 hours (D) cannot (Energy of Gamma rays emitted in Positron Emission (A) 140 keV (B) 511 keV (C) Incidence of thyroid cancer is higher in which thy (A) Hot nodule (B) Abset (C) Homogenous increased uptake (D) Cold (A) Thyroid adenoma (B) Para | PET Agent used for myocardial perfusion imaging: (A) 13N-Ammonia (B) 18F-FDG (C) 99mTc-MIBI (D) 201Thallium Chlor Critical Organ in 99mTc-MIBI myocardial perfusion imaging: (A) Heart (B) Proximal colon (C) Liver Half life of Iodine-131: (A) 3 days (B) 13.6 hours (C) 8 days Radioisotope used for painful bone metastasis: (A) Samarium 153 (B) Iodine 131 (C) Technetium 99m (D) Gallium 67 99mTc-sodium pertechnetate can be used for all the following et (A) Thyroid imaging (B) Salivary gland im (C) Infection imaging (D) Meckels diverticue (C) Infection imaging (D) cannot be resumed (A) 2 - 3 days (B) 12 to 24 hours (C) 4 hours (D) cannot be resumed (A) 140 keV (B) 511 keV (C) 364 keV Incidence of thyroid cancer is higher in which thyroid scintigration (C) Homogenous increased uptake (D) Cold nodule (B) Absence of thyroid common false positive finding in parathyroid scanning: (A) Thyroid adenoma (B) Parathyroid scanning: | (A) Kidney (B) Bone marrow (C) Colon (D) PET Agent used for myocardial perfusion imaging: (A) 13N-Ammonia (B) 18F-FDG (C) 99mTc-MIBI (D) 201Thallium Chloride Critical Organ in 99mTc-MIBI myocardial perfusion imaging: (A) Heart (B) Proximal colon (C) Liver (D) Half life of Iodine-131: (A) 3 days (B) 13.6 hours (C) 8 days (D) Radioisotope used for painful bone metastasis: (A) Samarium 153 (B) Iodine 131 (C) Technetium 99m (D) Gallium 67 99mTc-sodium pertechnetate can be used for all the following except: (A) Thyroid imaging (B) Salivary gland imaging (C) Infection imaging (D) Meckels diverticulum detection of the color of t | (A) Kidney (B) Bone marrow (C) Colon (D) Liver PET Agent used for myocardial perfusion imaging: (A) 13N-Ammonia (B) 18F-FDG (C) 99mTc-MIBI (D) 201Thallium Chloride Critical Organ in 99mTc-MIBI myocardial perfusion imaging: (A) Heart (B) Proximal colon (C) Liver (D) Stomach Half life of Iodine-131: (A) 3 days (B) 13.6 hours (C) 8 days (D) 60 days Radioisotope used for painful bone metastasis: (A) Samarium 153 (B) Iodine 131 (C) Technetium 99m (D) Gallium 67 99mTc-sodium pertechnetate can be used for all the following except: (A) Thyroid imaging (B) Salivary gland imaging (C) Infection imaging (D) Meckels diverticulum detection When performing Iodine-123 imaging, breast feeding can be safely resumed after? (A) 2 - 3 days (B) 12 to 24 hours (C) 4 hours (D) cannot be resumed Energy of Gamma rays emitted in Positron Emission Tomography: (A) 140 keV (B) 511 keV (C) 364 keV (D) 185 keV Incidence of thyroid cancer is higher in which thyroid scintigraphy pattern? (A) Hot nodule (B) Absence of thyroid uptake (C) Homogenous increased uptake (D) Cold nodule Most common false positive finding in parathyroid scanning: (A) Thyroid adenoma |

A

| 53. | | one Scan of a pagnant is : | atient | with know | vn mal | nalignancy, chance of a solitary Rib lesion being | | | |
|------------|------|-----------------------------------|----------|--------------|---------|---|------------------|-----------|---------------------|
| | (A) | 40-50% | (B) | 70-80% | | (C) | 10-20% | (D) | 2-5% |
| 54. | Caus | ses of positive Th | ree pl | nase bone s | scan ca | n be a | all the followin | ng except | : |
| | (A) | Recent fracture | ! | | (B) | Soft | tissue infectio | n | |
| | (C) | Charcots joint | | | (D) | Oste | eomyelitis | | |
| 55. | | holescintigraphy istent with : | for e | valuation | of neo | natal | jaundice, abse | ence of b | iliary clearance is |
| | (A) | Neonatal hepat | itis | | (B) | Acu | te cholecystitis | 5 | |
| | (C) | Chronic cholec | ystitis | | (D) | Bilia | ry Atresia | | |
| 56. | Radi | opharmaceutical | comn | nonly used | for me | easuri | ng GFR : | | |
| | (A) | Tc-99m MAG3 | | | (B) | I-131 | l Ortho Iodo I | Hippurate | e (OIH) |
| | (C) | Tc-99m DTPA | | | (D) | Tc-9 | 9m DMSA | | |
| 57. | Web | ster's rule applie | s to: | | | | | | |
| | (A) | Dose calculation | n in re | enal insuffi | ciency | | | | |
| | (B) | Myocardial ima | aging | | | | | | |
| | (C) | Cerebral perfus | ion in | naging | | | | | |
| | (D) | Dose calculation | n in p | aediatrics | | | | | |
| 58. | Capt | topril renography | y is do | ne in the v | vorkup | of: | | | |
| | (A) | Renal artery ste | enosis | | (B) | Rena | al vein thromb | osis | |
| | (C) | Pyelonephritis | | | (D) | Non | e of the above | ! | |
| 59. | The | accuracy of diur | etic re | nography i | s affec | ted by | 7: | | |
| | (A) | Renal function | | | (B) | Dose | e of diuretic | | |
| | (C) | Bladder capaci | ty | | (D) | All | of the above | | |
| 60. | The | sensitivity of FD0 | G PET | is high in | | | | | |
| | (A) | Primary hepato | ocellul | ar carcinor | na | | | | |
| | (B) | Prostate carcine | oma | | | | | | |
| | (C) | Colorectal cand | er | | | | | | |
| | (D) | Renal carcinon | na | | | | | | |

| 61 . | Sent | inel node scintigr | aphy | in melanom | na is ir | ndicat | ed in primary l | lesion of | size: |
|-------------|----------------------|---|--------------------------|---|----------|---------|------------------|-----------|--------------------|
| | (A) | < 1 mm | (B) | 1 to 4 mm | - | (C) | > 4 mm | (D) | Both (A) and (B) |
| 62. | Prefe | erred method for | radio | labelling of | RBCs | : | | | |
| | (A) | In vivo method | | | (B) | Mod | lified In vivo m | nethod | |
| | (C) | In vitro method | | | (D) | Any | of the above | | |
| 63. | Mult | tiple photopeak e | nergie | es are acquii | red for | r imaş | ging of : | | |
| | (A) | Gallium-67 | | | (B) | Tech | nnitium-99m | | |
| | (C) | Gallium-68 | | | (D) | Iodi | ne-131 | | |
| 64. | Puln | nonary Gallium - | 67 up | take is not | seen ii | n : | | | |
| | (A) | Sarcoidosis | | | (B) | Hist | oplasmosis | | |
| | (C) | Kaposis sarcom | a | | (D) | Cyto | omegalovirus ii | nfection | |
| 65. | | ch of the followi | ng fir | nding sugge | ests tr | iple v | vessel disease | in a myo | ocardial perfusion |
| | (A) | reduced anterio | r wall | l uptake | (B) | exer | cise induced is | schemic o | lialatation |
| | (C) | lung uptake on | delay | ed images | (D) | redu | iced anterior a | nd latera | l wall uptake |
| 66. | Reve | ersible stress indu | ced h | ypoperfusio | n of tl | he sep | otum is seen in | : | |
| | (A) | Triple vessel dis | ease | | (B) | Stres | ss induced isch | nemia | |
| | (C) | WPW syndrome | e | | (D) | Left | Bundle branch | n block | |
| 67. | Acco | ording to the 2007 | 7 ICRI | ? recommer | ndatio | ns, tis | sue weighting | factor fo | r Gonads is : |
| | (A) | 0.12 | (B) | 0.04 | | (C) | 0.08 | (D) | 0.01 |
| 68. | Reco | ommended Effect | ive do | se limit for | occup | ationa | al exposure in a | a year (a | verage) is : |
| | (A) | 500 mSv | (B) | 150 mSv | | (C) | 15 mSv | (D) | 20 mSv |
| 69. | A ga (A) (B) (C) (D) | Sodium Iodide a Cesium Iodide a Germanium doj Cadmium Zinc | activa doped ped w | ted with Th with Thalli ith Lithium | um | n | | | |

| 70. | Most common type of collimator used in gamma cameras : | | | | | | | | |
|-----|--|--------------------------------------|---------|--------------|---------|--------|-----------------|------------|---------------------|
| | (A) | Pin Hole Collim | ator | | (B) | Para | llel Hole Colli | imator | |
| | (C) | Diverging Colli | mator | | (D) | Con | verging Collir | nator | |
| 71. | In p | erforming Quality | y cont | rol of a Ga | mma (| Camer | ra, Spatial Res | olution sł | nould be done: |
| | (A) | daily | (B) | at installa | ation | (C) | weekly | (D) | monthly |
| 72. | On a | a bone scan, pin l | nole co | ollimation o | can be | used | in : | | |
| | (A) | Legg-Calve-Per | thes I | Disease | (B) | Mul | tiple Myeloma | ì | |
| | (C) | Rib Fracture | | | (D) | Non | e of the above | | |
| 73. | Whie | | ceutica | al among b | one in | naging | g agents is su | perior in | localizing necrotic |
| | (A) | Tc-99m MDP | | | (B) | Tc-9 | 9m HDP | | |
| | (C) | Tc-99m HEDP | | | (D) | Tc-9 | 9m pyrophos | phate | |
| 74. | Max | imum predicted | heart | rate is calc | ulated | by: | | | |
| | (A) | 180-age | (B) | 240-age | | (C) | 220-age | (D) | age in years×4 |
| 75. | Left | anterior descend | ing co | oronary arte | ery sup | plies | : | | |
| | (A) | Anterior and la | teral v | walls | (B) | Late | ral and Poster | rior walls | |
| | (C) | Anterior wall a | nd the | e septum | (D) | Infe | rior wall and 1 | right vent | tricle |
| 76. | Poor | in vivo RBC labe | elling | can be caus | sed by | : | | | |
| | (A) | drug interaction | ns | | (B) | inco | rrect amount | of stanno | us ion |
| | (C) | inappropriate p | roced | lure | (D) | all t | ne above | | |
| 77. | | uced ventricula riculogram is der | | | while | asses | ssing wall m | notion o | n a radionuclide |
| | (A) | dyskinesis | (B) | hypokine | sis | (C) | akinesis | (D) | tardokinesis |
| A | | | | | 11 | | | | 019/2018 |

| 78. | 78. Tracers used in blood brain barrier imaging are all except: | | | | | | | | |
|------------|---|------------------------------------|---------|--------------|--------|---------|--------------------|----------|----------------------|
| | (A) | Tc-99m pertech | netate | <u> </u> | (B) | Tc-9 | 9m DTPA | | |
| | (C) | Tc-99m ECD | | | (D) | Tc-9 | 9m Glucohepto | nate | |
| 79. | Best | tracer to diagnos | e veno | ous sinus th | rombo | osis : | | | |
| | (A) | Tc-99m HMPA | C | | (B) | Tc-9 | 9m ECD | | |
| | (C) | Tc-99m Glucoho | epton | ate | (D) | Tc-9 | 9m RBCs | | |
| 80. | Para | doxical blocking | of iod | ine incorpo | ration | into | thyroid hormon | es from | excess iodine : |
| | (A) | Jod-Basedow pl | nenon | nenon | (B) | Wol | ff - Chaikoff effe | ect | |
| | (C) | Riedel's thyroid | itis | | (D) | Mar | ine - Lenhart sy | ndrom | e |
| 81. | Whi | ch of the followir | ng rad | iopharmace | utical | s can | be used in thyro | oid ima | ging ? |
| | (A) | Tc-99m DMSA | (B) | F-18 FDG | | (C) | Tc-99m MDP | (D) | Tc-99m HMPAO |
| 82. | Sym | metric decrease in | n perf | usion and n | netabo | olism : | in Alzheimers d | isease i | s seen in : |
| | (A) | Posterior parieta | al lobe | j | (B) | Occi | pital lobe | | |
| | (C) | Temporal pariet | al lob | e | (D) | Fror | atal lobe | | |
| 83. | Spec | ificity for detection | on of | pheochromo | ocyton | na usi | ing I-131 MIBG | imagin | g is around : |
| | (A) | 95% | (B) | 60% | | (C) | 90% | (D) | 80% |
| 84. | Sens | itivity of a bone s | scan is | highest for | :: | | | | |
| | (A) | Prostate | | | (B) | Brea | ıst | | |
| | (C) | Lung | | | (D) | Rena | al cell carcinom | a | |
| 85. | | igh I-123 is the ic | leal th | nyroid imag | ing ag | gent, i | t is not commor | ıly used | l because of all the |
| | (A) | short half life | | | (B) | can | be stored for fut | ture use | 9 |
| | (C) | expensive | | | (D) | not | readily available | 9 | |
| 86. | _ | ols iodine or po MIBG should be | | - | rate t | o blo | ck thyroid upt | ake wh | ile administering |
| | (A) | 24 hours | (B) | 48 hours | | (C) | 7 days | (D) | 14 days |
| 019/ | 2018 | | | | 12 | | | | A |

| 87. High probability of pulmonary emboli in the modified PIOPED Criteria : | | | | | | | | | | |
|--|------|--|--|---------|------------------|----------|----------------------|--|--|--|
| | (A) | multiple perfusion defects with a | ssocia | ited ra | adiographic opa | cities | | | | |
| | (B) | triple match: solitary moderate radiograph | -larg | e mat | ching segment | al defe | ect with matching | | | |
| | (C) | matched ventilation and perfusion | n def | ects w | vith a normal cl | nest rad | iograph | | | |
| | (D) | any perfusion defect substantially | larg | er tha | n the radiograp | hic abn | ormality | | | |
| 88. | _ | nence of performing ventilation and ectively should be: | d per | fusior | n studies while | using > | Ke-133 and Tc-99m | | | |
| | (A) | Perfusion study followed by vents | ilatior | ı stud | y | | | | | |
| | (B) | Ventilation study followed by per | fusio | n stud | ły | | | | | |
| | (C) | Both studies simultaneously | | | | | | | | |
| | (D) | Either studies can be performed in | n any | seque | ence | | | | | |
| 89. | Drug | g which is not used for pharmacolo | ogical | stress | s testing ? | | | | | |
| | (A) | Dipyridamole (B) Adenosine | ! | (C) | Regadenoson | (D) | Metoprolol | | | |
| 90. | Nucl | lear Sialography is performed using | g : | | | | | | | |
| | (A) | Tc-99m pertechnetate | | Tc-9 | 9m sulfur colloi | d | | | | |
| | (C) | Ga-67 Citrate | (D) | Tc-9 | 9m labelled RB0 | Cs | | | | |
| 91. | | most important parameter which dives during a nuclear medicine pro | nich determines the actual amount of exposure the patient procedure: | | | | | | | |
| | (A) | Biological half life | (B) | Phys | sical half life | | | | | |
| | (C) | Effective half life | (D) | Both | (A) and (C) | | | | | |
| 92. | | e of recombinant human TSH i ne - 131. | nject | ion u | sed in Thyroi | d cance | er imaging using | | | |
| | (A) | 0.3 mg for two consecutive days | (B) | 0.9 r | ng for two cons | ecutive | days | | | |
| | (C) | 0.45 mg for two consecutive days | (D) | 0.6 r | ng for two cons | ecutive | days | | | |
| 93. | The | type of emissions used in radionuc | lide t | herap | y are all except | : | | | | |
| | (A) | Beta rays (B) Gamma ra | ys | (C) | Auger electron | ns (D) | Alpha particles | | | |
| A | | | 13 | | | | 019/2018 {P.T.O.} | | | |

| 94. | An interaction in which a gamma photon loses all of its energy to an inner shell electron is: | | | | |
|-----------|---|---|--------|------------------------------------|--|
| | (A) | Annihilation reaction | (B) | Pair production | |
| | (C) | Compton effect | (D) | Photoelectric effect | |
| 95. | PET Tracer used in hypoxia imaging : | | | | |
| | (A) | Gallium-68 Dotatate | (B) | F-18 misonidazole | |
| | (C) | F-18 FDG | (D) | F-18 DOPA | |
| 96. | Radionuclide used in palliative bone metastases treatment which can also be imaged : | | | | |
| | (A) | Strontium-89 | (B) | Phosphorus-32 | |
| | (C) | Rhenium-186 | (D) | None of the above | |
| 97. | False negative lung findings on a PET-CT is seen in : | | | | |
| | (A) | Tuberculosis | (B) | Squamous cell carcinoma | |
| | (C) | Sarcoidosis | (D) | Bronchioalveolar carcinoma | |
| 98. | In Prostate Carcinoma imaging which of the following is false? | | | | |
| | (A) Most primary prostate carcinomas demonstrate high uptake of F-18 FDG | | | | |
| | (B) | (B) FDG PET is not reliable in differentiating carcinoma from benign prostate hypertrophy | | | |
| | (C) | (C) FDG PET has less sensitivity in assessing lymphnode metastases | | | |
| | (D) | (D) Bone scan is more sensitive than PET in detecting bone metastases | | | |
| 99. | Low to moderate FDG uptake is seen in : | | | | |
| | (A) | Hodgkins lymphoma | (B) | Peripheral T cell lymphoma | |
| | (C) | Diffuse large B-cell lymphoma | (D) | Mantle cell lymphoma | |
| 100. | High uptake in colon in an FDG PET can occur in : | | | | |
| | (A) | Adenoma (B) Diverticu | ılitis | (C) Carcinoma (D) Any of the above | |
| - o O o - | | | | | |

SPACE FOR ROUGH WORK

SPACE FOR ROUGH WORK